Insufficient evidence for cannabinoids in the treatment of mental disorders.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    Brown University Psychopharmacology Update. Feb2020, Vol. 31 Issue 2, p1-6. 6p.
  • Additional Information
    • Subject Terms:
      MENTAL illness drug therapy; MEDICAL marijuana; TREATMENT effectiveness; THERAPEUTICS
    • Abstract:
      The most comprehensive review to date of medicinal cannabinoids for the treatment of mental disorders has concluded that the evidence is insufficient to justify their use. A greater number of high‐quality trials is necessary to assess the safety and efficacy of medical cannabis and derivatives such as the increasingly popular cannabidiol (CBD), authors of the review and meta‐analysis stated. Results were published online Oct. 28 in Lancet Psychiatry. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Brown University Psychopharmacology Update is the property of John Wiley & Sons, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)